MYL-1402O: A Bevacizumab Biosimilar

Target Oncol. 2022 Jan;17(1):85-88. doi: 10.1007/s11523-021-00858-7. Epub 2021 Dec 15.


MYL-1402O (Abevmy®, Lextemy®) is a biosimilar of the reference anti-vascular endothelial growth factor antibody bevacizumab. Abevmy® is approved for use in all indications for which reference bevacizumab is approved, including the treatment of non-small cell lung cancer (NSCLC) and other solid cancers. Lextemy® is approved for all indications as reference bevacizumab, except in recurrent ovarian cancer. MYL-1402O has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab, and the pharmacokinetic similarity of the agents has been shown in healthy male subjects. MYL-1402O demonstrated clinical efficacy equivalent to that of reference bevacizumab in patients with non-squamous NSCLC. The tolerability, safety and immunogenicity profiles of MYL-1402O were consistent with those of reference bevacizumab. The role of reference bevacizumab in the management of solid cancers is well established and MYL-1402O provides an effective biosimilar alternative for patients requiring bevacizumab therapy.

Publication types

  • Review

MeSH terms

  • Bevacizumab / pharmacology
  • Bevacizumab / therapeutic use
  • Biosimilar Pharmaceuticals* / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Lung Neoplasms* / drug therapy
  • Male
  • Neoplasm Recurrence, Local / drug therapy


  • Biosimilar Pharmaceuticals
  • Bevacizumab